Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Frontiers in Oncology
|
August 28, 2020
Reduced LDL-Cholesterol and Reduced Total Cholesterol as Potential Indicators of Early Cancer in Male Treatment-Naïve Cancer Patients With Pre-cachexia and Cachexia
Hannes Zwickl, Klaus Hackner, Harald Köfeler, et al.
Clinical Breast Cancer
|
July 2, 2017
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study
Guenther G Steger, Adriana Dominguez, Natalia Dobrovolskaya, et al.
Critical Reviews in Oncology/Hematology
|
September 15, 2007
Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
Ingo J Diel, Ignac Fogelman, Bilal Al-Nawas, et al.
Breast Cancer Research and Treatment
|
October 31, 2018
Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer
Sonia Vallet, Fengjuan Fan, Stefano Malvestiti, et al.
Cancers
|
September 10, 2021
Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients
Josef Singer, Nguyen-Son Le, Daniel Mattes, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2021
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial
Felix Keil, Maximilian Hartl, Gabriela Altorjai, et al.
Wiener Klinische Wochenschrift
|
July 9, 2013
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease
Rodica Anghel, Alexander Bachmann, Meral Bekşac, et al.
Journal for Immunotherapy of Cancer
|
May 3, 2024
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
Tamara Gassner, Christina Chittilappilly, Theo Pirich, et al.
Leukemia
|
September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Leukemia
|
May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Frontiers in Oncology
|
August 28, 2020
Reduced LDL-Cholesterol and Reduced Total Cholesterol as Potential Indicators of Early Cancer in Male Treatment-Naïve Cancer Patients With Pre-cachexia and Cachexia
Hannes Zwickl, Klaus Hackner, Harald Köfeler, et al.
Clinical Breast Cancer
|
July 2, 2017
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study
Guenther G Steger, Adriana Dominguez, Natalia Dobrovolskaya, et al.
Critical Reviews in Oncology/Hematology
|
September 15, 2007
Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
Ingo J Diel, Ignac Fogelman, Bilal Al-Nawas, et al.
Breast Cancer Research and Treatment
|
October 31, 2018
Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer
Sonia Vallet, Fengjuan Fan, Stefano Malvestiti, et al.
Cancers
|
September 10, 2021
Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients
Josef Singer, Nguyen-Son Le, Daniel Mattes, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2021
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial
Felix Keil, Maximilian Hartl, Gabriela Altorjai, et al.
Wiener Klinische Wochenschrift
|
July 9, 2013
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease
Rodica Anghel, Alexander Bachmann, Meral Bekşac, et al.
Journal for Immunotherapy of Cancer
|
May 3, 2024
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
Tamara Gassner, Christina Chittilappilly, Theo Pirich, et al.
Leukemia
|
September 7, 2021
Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Leukemia
|
May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesis
Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Page
of 5